Granted Patent
B2
US 8,173,671 · App. 12/967,250 · Granted May 8, 2012
Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.
Claims (10)
1. A method of treating an otic infection comprising topically administering to the ear a solution composition consisting essentially of
a) 0.545% (w/v) moxifloxacin hydrochloride;
b) 0.11% (w/v) dexamethasone sodium phosphate;
c) 0.01% (w/v) edetate disodium;
d) 0.5-0.75% (w/v) sodium chloride;
e) 0.3% (w/v) boric acid;
f) 0.01% (w/v) benzalkonium chloride;
g) 0.05% (w/v) tyloxapol;
h) NaOH or HCl in an amount sufficient to cause the composition to have a pH from 7.8-8.0; and
i) water.
Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS. PREVIOUSLY RECORDED AT REEL: 050746 FRAME: 0431. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT..
Recorded Oct 18, 2019
From: ALCON RESEARCH, LLC
To: NOVARTIS AG
Reel/Frame 050767/0001 →
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019
Recorded Oct 17, 2019
From: ALCON RESEARCH, LLC
To: NOVARTIS AG
Reel/Frame 050746/0431 →
MERGER
Recorded Oct 16, 2019
From: ALCON RESEARCH, LTD.
To: ALCON RESEARCH, LLC
Reel/Frame 050735/0465 →